CY1125122T1 - Θεραπεια συνδυασμου me anti-cd19 αντισωμα και μουσταρδα αζωτου - Google Patents
Θεραπεια συνδυασμου me anti-cd19 αντισωμα και μουσταρδα αζωτουInfo
- Publication number
- CY1125122T1 CY1125122T1 CY20221100289T CY221100289T CY1125122T1 CY 1125122 T1 CY1125122 T1 CY 1125122T1 CY 20221100289 T CY20221100289 T CY 20221100289T CY 221100289 T CY221100289 T CY 221100289T CY 1125122 T1 CY1125122 T1 CY 1125122T1
- Authority
- CY
- Cyprus
- Prior art keywords
- antibody
- nitrogen mustard
- combination therapy
- present disclosure
- treatment
- Prior art date
Links
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 title abstract 2
- 229960004961 mechlorethamine Drugs 0.000 title abstract 2
- 238000002648 combination therapy Methods 0.000 title 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 abstract 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 abstract 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 abstract 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 abstract 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 abstract 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 abstract 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161523861P | 2011-08-16 | 2011-08-16 | |
| EP11177658 | 2011-08-16 | ||
| US201261647539P | 2012-05-16 | 2012-05-16 | |
| US201261654097P | 2012-06-01 | 2012-06-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1125122T1 true CY1125122T1 (el) | 2024-12-13 |
Family
ID=47714801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20221100289T CY1125122T1 (el) | 2011-08-16 | 2022-04-18 | Θεραπεια συνδυασμου me anti-cd19 αντισωμα και μουσταρδα αζωτου |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US20140255427A1 (enExample) |
| EP (2) | EP2744515B1 (enExample) |
| JP (1) | JP6184952B2 (enExample) |
| KR (3) | KR102115203B1 (enExample) |
| CN (1) | CN103732252B (enExample) |
| AU (1) | AU2012296907B2 (enExample) |
| BR (1) | BR112013033919B1 (enExample) |
| CA (2) | CA3137321A1 (enExample) |
| CY (1) | CY1125122T1 (enExample) |
| DK (1) | DK2744515T3 (enExample) |
| ES (1) | ES2909722T3 (enExample) |
| HR (1) | HRP20220228T1 (enExample) |
| HU (1) | HUE058350T2 (enExample) |
| IL (1) | IL230293B (enExample) |
| LT (1) | LT2744515T (enExample) |
| MX (1) | MX354479B (enExample) |
| PL (1) | PL2744515T3 (enExample) |
| PT (1) | PT2744515T (enExample) |
| RS (1) | RS63238B1 (enExample) |
| RU (1) | RU2625222C2 (enExample) |
| SG (1) | SG10201606785UA (enExample) |
| SI (1) | SI2744515T1 (enExample) |
| SM (1) | SMT202200159T1 (enExample) |
| WO (1) | WO2013024097A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015195498A1 (en) * | 2014-06-16 | 2015-12-23 | Xencor, Inc. | Treatment for chronic lymphocytic leukemia (cll) |
| KR102809079B1 (ko) * | 2015-05-26 | 2025-05-21 | 인사이트 코포레이션 | 항-cd19 항체 및 브루톤 타이로신 키나제 억제제의 조합 및 이의 용도 |
| LT3337506T (lt) * | 2015-08-21 | 2021-10-11 | Morphosys Ag | Deriniai ir jų panaudojimas |
| KR102584300B1 (ko) | 2016-03-29 | 2023-10-05 | 유니버시티 오브 써던 캘리포니아 | 암을 표적하는 키메라 항원 수용체 |
| BR112018074603A2 (pt) * | 2016-05-30 | 2019-03-19 | Morphosys Ag | método para identificar um sujeito tendo leucemia linfocítica crônica, método para selecionar um paciente para tratamento e utilização de um anticorpo |
| IL301786B2 (en) * | 2016-10-28 | 2025-09-01 | Morphosys Ag | Combination of anti-CD19 antibody with BCL-2 inhibitor and their uses |
| IL266892B2 (en) | 2016-12-02 | 2025-10-01 | Univ Southern California | Artificial immune receptors and methods of using them |
| HRP20231229T1 (hr) * | 2017-05-31 | 2024-02-02 | Morphosys Ag | Paradigma liječenja za protutijelo anti-cd19 i venetoklaks kombinacijsko liječenje |
| KR20200030337A (ko) | 2018-09-12 | 2020-03-20 | 주식회사 녹십자랩셀 | 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물 |
| EP4453033A1 (en) * | 2021-12-22 | 2024-10-30 | Incyte Corporation | Treatment paradigm for an anti-cd19 antibody therapy |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4708871A (en) | 1983-03-08 | 1987-11-24 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| US5686072A (en) | 1992-06-17 | 1997-11-11 | Board Of Regents, The University Of Texas | Epitope-specific monoclonal antibodies and immunotoxins and uses thereof |
| NZ507381A (en) * | 1998-04-21 | 2003-12-19 | Micromet Ag | CD19xCD3 specific polypeptides and uses thereof |
| IL146005A0 (en) * | 1999-05-07 | 2002-07-25 | Genentech Inc | Treatment of autoimmune diseases with antagonists which bind to b cell surface markers |
| KR20040023565A (ko) | 2000-09-18 | 2004-03-18 | 아이덱 파마슈티칼즈 코포레이션 | Ｂ 세포 고갈/면역조절 항체 조합을 이용한 자가면역질환의 치료를 위한 조합 요법 |
| DE60226641D1 (de) | 2001-12-03 | 2008-06-26 | Amgen Fremont Inc | Antikörperkategorisierung auf der grundlage von bindungseigenschaften |
| US20080260731A1 (en) * | 2002-03-01 | 2008-10-23 | Bernett Matthew J | Optimized antibodies that target cd19 |
| US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| US7109304B2 (en) | 2003-07-31 | 2006-09-19 | Immunomedics, Inc. | Humanized anti-CD19 antibodies |
| WO2006065392A2 (en) | 2004-11-05 | 2006-06-22 | Cephalon, Inc. | Cancer treatments |
| EP1899379B1 (en) | 2005-06-20 | 2018-04-11 | E. R. Squibb & Sons, L.L.C. | Cd19 antibodies and their uses |
| DK2270050T3 (da) | 2005-12-30 | 2013-08-12 | Merck Patent Gmbh | Anti-CD19-antistoffer med nedsat immunogenicitet |
| DK2059536T3 (da) * | 2006-08-14 | 2014-04-14 | Xencor Inc | Optimerede antistoffer, der er rettet mod cd19 |
| WO2008031056A2 (en) | 2006-09-08 | 2008-03-13 | Medimmune, Llc | Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| WO2008150494A1 (en) | 2007-05-30 | 2008-12-11 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
| WO2009052431A2 (en) | 2007-10-19 | 2009-04-23 | Seattle Genetics, Inc. | Cd19 binding agents and uses thereof |
| JP2012515217A (ja) * | 2009-01-16 | 2012-07-05 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | ベンダムスチンおよび抗−ｃｄ２０抗体の組合せを用いた癌治療 |
| CA2753158A1 (en) | 2009-02-23 | 2010-08-26 | Glenmark Pharmaceuticals S.A. | Humanized antibodies that bind to cd19 and their uses |
| EP2445530B1 (en) | 2009-06-24 | 2016-09-07 | The Feinstein Institute for Medical Research | Method for treating chronic lymphocytic leukemia |
| TWI409079B (zh) * | 2009-08-14 | 2013-09-21 | Roche Glycart Ag | 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法 |
| RU2012109451A (ru) * | 2009-08-14 | 2013-09-27 | Роше Гликарт Аг | Комбинированная терапия на основе афукозилированного антитела к cd20 в сочетании с флударабином и/или митоксантроном |
| CA2779424A1 (en) * | 2009-11-06 | 2011-05-12 | Infinity Pharmaceuticals, Inc. | Oral formulations of a hedgehog pathway inhibitor |
-
2012
- 2012-08-14 KR KR1020197026462A patent/KR102115203B1/ko active Active
- 2012-08-14 RU RU2014103492A patent/RU2625222C2/ru active
- 2012-08-14 EP EP12747923.6A patent/EP2744515B1/en active Active
- 2012-08-14 CA CA3137321A patent/CA3137321A1/en active Pending
- 2012-08-14 MX MX2013014933A patent/MX354479B/es active IP Right Grant
- 2012-08-14 DK DK12747923.6T patent/DK2744515T3/da active
- 2012-08-14 RS RS20220412A patent/RS63238B1/sr unknown
- 2012-08-14 AU AU2012296907A patent/AU2012296907B2/en active Active
- 2012-08-14 US US14/126,928 patent/US20140255427A1/en not_active Abandoned
- 2012-08-14 LT LTEPPCT/EP2012/065906T patent/LT2744515T/lt unknown
- 2012-08-14 HU HUE12747923A patent/HUE058350T2/hu unknown
- 2012-08-14 SI SI201231989T patent/SI2744515T1/sl unknown
- 2012-08-14 CN CN201280036571.XA patent/CN103732252B/zh active Active
- 2012-08-14 WO PCT/EP2012/065906 patent/WO2013024097A1/en not_active Ceased
- 2012-08-14 HR HRP20220228TT patent/HRP20220228T1/hr unknown
- 2012-08-14 PL PL12747923T patent/PL2744515T3/pl unknown
- 2012-08-14 SG SG10201606785UA patent/SG10201606785UA/en unknown
- 2012-08-14 KR KR1020147006936A patent/KR20140064873A/ko not_active Ceased
- 2012-08-14 CA CA2841875A patent/CA2841875C/en active Active
- 2012-08-14 EP EP22155572.5A patent/EP4062936A1/en active Pending
- 2012-08-14 ES ES12747923T patent/ES2909722T3/es active Active
- 2012-08-14 PT PT127479236T patent/PT2744515T/pt unknown
- 2012-08-14 KR KR1020207014299A patent/KR20200058583A/ko not_active Withdrawn
- 2012-08-14 BR BR112013033919-5A patent/BR112013033919B1/pt active IP Right Grant
- 2012-08-14 JP JP2014525434A patent/JP6184952B2/ja active Active
- 2012-08-14 SM SM20220159T patent/SMT202200159T1/it unknown
-
2014
- 2014-01-02 IL IL230293A patent/IL230293B/en active IP Right Grant
-
2020
- 2020-04-03 US US16/839,777 patent/US20200353077A1/en not_active Abandoned
-
2022
- 2022-04-18 CY CY20221100289T patent/CY1125122T1/el unknown
-
2024
- 2024-01-12 US US18/411,350 patent/US20240366756A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125122T1 (el) | Θεραπεια συνδυασμου me anti-cd19 αντισωμα και μουσταρδα αζωτου | |
| CY1125148T1 (el) | Θεραπεια συνδυασμου με αντι-cd19 αντισωμα και αναλογο πουρινης | |
| CY1121723T1 (el) | Συνδυασμος anti-lag-3 αντισωματων και anti-pd-1 αντισωματων για θεραπεια ογκων | |
| CR20150048A (es) | Anticuerpos e inmunoconjugados anti-cd22 | |
| CY1124648T1 (el) | Συνδυασμος αντισωματος αντι- cd19 με εναν αναστολεα bcl-2 και χρησεις αυτου | |
| CO7151529A2 (es) | Anticuerpos anti-cd22 e inmunoconjugados | |
| CY1122298T1 (el) | Συνδυασμος αντισωματος anτι-cd19 και αναστολεα τυροσινης κινασης toy bruton και χρησεις του | |
| PH12014502601A1 (en) | ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | |
| BR112015010436A2 (pt) | Anticorpos anti-notch3 e conjugados anticorpo-fármaco | |
| CR20150049A (es) | Anticuerpos e inmunoconjugados anti-cd79b | |
| CR20140441A (es) | Anticuerpos anti-lgr5 e inmunoconjugados | |
| CY1124706T1 (el) | Συνδυασμοι και χρησεις αυτων | |
| BR112015032224A2 (pt) | anticorpos anti-fcrh5 | |
| MX373121B (es) | Composiciones y metodos para el tratamiento de leucemia. | |
| PH12014501164A1 (en) | Anti-cd98 antibodies and methods of use thereof | |
| EA201300810A1 (ru) | Противораковая терапия с использованием двойных ингибиторов киназ аврора/мек | |
| MX342240B (es) | Anticuerpos anti-fgfr4 y metodos de uso. | |
| MX372661B (es) | Anticuerpos anti-htra1 y metodos de uso. | |
| AR096183A1 (es) | Terapia de combinación de un anticuerpo para cd20 afucosilado con un conjugado de anticuerpo para cd79b-fármaco | |
| MX370723B (es) | Anticuerpos anti-tau y usos de los mismos en el tratamiento de una tauopatía. | |
| CY1118968T1 (el) | Αυξημενη βιοδιαθεσιμοτητα δραστικης ουσιας σε θεραπεια ναλτρεξονης | |
| TN2013000472A1 (en) | Induction of immune tolerance by using methotrexate | |
| CY1117541T1 (el) | Αντικαρκινικες στεροειδεις λακτονες μη κορεσμενες στη θεση 7(8) | |
| CL2015002358A1 (es) | Compuestos bicíclicos. | |
| CY1118277T1 (el) | Σταθερη φαρμακοτεχνικη μορφη πεξιγανανης |